Eli Lilly blocked in European heart failure label push: Is the GLP‑1 race now tilting to Novo Nordisk?
Find out why Eli Lilly’s bid to expand Mounjaro’s EU label for heart failure was declined and what it means for the company’s growth strategy and competitive standing.
Can Coya Therapeutics de-risk IL-2 manufacturing ahead of trial results? Inside the $11.1m raise
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy’s to scale COYA 302 IL-2 manufacturing. Find out what it means for investors.
Will Carisa Schultz’s appointment help Nuwellis manage its cash crunch and regain trust?
Nuwellis appoints Carisa Schultz as CFO amid stock volatility and strategic expansion. Learn what this leadership change means for investors and medtech peers.
Johnson & Johnson’s AKEEGA clears major EU hurdle with CHMP nod for mHSPC BRCA mutation indication
Johnson & Johnson’s EU backing for AKEEGA’s expanded prostate cancer label could reshape its oncology strategy and precision medicine footprint in 2026.
Can weight loss drugs cause fatal pancreas illness? UK raises red flag on GLP-1 therapies
UK strengthens pancreatitis risk warning for GLP-1 weight loss and diabetes drugs like Wegovy and Mounjaro. Find out what it means for health systems and pharma.
What HSBC’s downgrade really says about Pinterest’s future in digital advertising
Find out why HSBC downgraded Pinterest (PINS) to hold as job cuts reshape strategy and influence near‑term growth outlook, and what it means for investors.
What the Langeloth explosion means for Centerra Gold’s Thompson Creek molybdenum comeback
Centerra Gold has halted operations at its Pennsylvania metallurgical plant after an explosion. Discover the strategic, regulatory, and investor implications.
Moderna shakes up leadership as COVID vaccine demand wanes—can new R&D head realign its future?
Find out why Moderna, Inc. is replacing its medical chief with a development leader and what it means for the company’s post-COVID pipeline strategy.
Can Chili’s value meals crush fast food? Brinker’s playbook is shaking up the industry
Chili’s is challenging fast food dominance with value meals and rising traffic. Find out how Brinker International is disrupting the restaurant game.
VHUB listing: VenHub Global Inc’s Nasdaq entry bets on autonomous retail format and smart infrastructure
Discover how VenHub Global Inc’s Nasdaq direct listing under VHUB advances autonomous retail infrastructure and what this means for investors and industry.